Economic impact of disease progression in follicular non-Hodgkin lymphoma

Roy Beveridge¹, Sacha Satram-Hoang², Kavita Sail¹, Joseph Darragh¹, Clara Chen¹, Michael Forsyth¹ & Carolina Reyes²

¹Healthcare Informatics, US Oncology, Houston, TX, USA and ²Genentech, Inc., South San Francisco, CA, USA

Abstract
Using a retrospective claims database, we estimated the economic costs of progression among patients with follicular non-Hodgkin lymphoma (f-NHL) treated in an outpatient community-based setting. Patients with f-NHL who received care between 1 July 2006 and 31 December 2009 were categorized into two cohorts based on whether they experienced progressive disease (PD) or not. Costs per patient per month (PPPM) were compared between patients with PD versus non-PD. Follow-up time was censored at the last entry for disease status or 6 months after the date of remission/stable disease or progression. Of the 1002 patients with f-NHL identified, 268 progressed and 734 did not. The mean overall costs PPPM over the 6-month follow-up period were significantly higher for patients with PD versus non-PD ($3527 vs. $860; difference = $2667; p < 0.001). This cost difference persisted within all resource categories evaluated. Results of this study indicate that therapies which delay progression for patients with f-NHL may result in potential cost savings.

Keywords: Health resource utilization, costs of care, disease progression, follicular lymphoma

Introduction
Follicular non-Hodgkin lymphoma (f-NHL) is a slow-growing (indolent) subtype of NHL that constitutes approximately 20–25% of all NHL and 70% of indolent lymphomas [1]. While f-NHL is considered incurable with currently available therapies, the 5-year survival rate is around 70% [2] with median survival being 8–10 years [3,4]. Often patients are not treated when first diagnosed if no symptoms are present. The natural history of f-NHL is characterized by continuous risk of relapse and progression, with each event becoming less sensitive to treatment and each remission shorter than the preceding one [5,6]. This makes disease management challenging, with a wide array of treatment options ranging from watchful waiting to intensive therapies that are typically aimed at delaying disease relapse and progression with fewest adverse effects.

The safety and effectiveness of rituximab (an anti-CD20 antibody) resulted in the widespread use of this agent in the treatment of f-NHL as either monotherapy or in combination with chemotherapy [7,8]. Rituximab added to chemotherapy has demonstrated significant increases in response rates, response duration, and overall survival as either first-line or relapse treatment in NHL [9–12]. Consolidation therapy with rituximab followed by 90 Y-ibritumomab tiuxetan in patients with f-NHL who achieved complete or partial response after first-line induction therapy prolonged progression-free survival (PFS) [13]. The use of maintenance rituximab after chemotherapy has been shown to be superior to observation among patients with NHL not previously treated with rituximab [14,15]. Further, maintenance rituximab was beneficial in patients with f-NHL who achieved a partial or complete remission after initial single-agent first-line rituximab therapy [16,17]. Maintenance rituximab significantly improved PFS compared with observation after induction with both chemotherapy alone and rituximab plus chemotherapy in relapsed/resistant f-NHL [18,19]. Most recently, data presented from a large international phase III trial demonstrated that patients with advanced f-NHL treated with rituximab maintenance had a 50% reduction in risk of progressive disease (PD) relative to patients who did not receive rituximab maintenance [20,21].

While current treatments have demonstrated improved clinical outcomes among patients with f-NHL, growing constraints on healthcare resources are making it increasingly important to also evaluate economic outcomes associated with therapy. Several studies have compared the cost-effectiveness of treatment alternatives, and found that the use of rituximab is cost-effective in the first-line [22] and relapsed maintenance settings [23]. Kutikova et al., in a study evaluating medical costs associated with NHL in the first 2 years of treatment, found that treatment failure was the most expensive clinical scenario [24]. Past economics studies, however, are limited in geographic range and are often restricted to the clinical trial setting. Furthermore, no studies have directly...
Materials and methods

Data sources
This study utilized clinical data from US Oncology’s iKnowMed oncology-specific electronic medical record (EMR) system. This system captures demographic, clinical, and treatment data for patients receiving care within US Oncology’s network of approximately 1200 community-based oncologists. During the study time period, the iKnowMed EMR system was implemented across approximately 82% of the US Oncology network. It is estimated that iKnowMed captures data on approximately 5–6% of all newly diagnosed patients with NHL in the United States, in a setting where patients are treated according to usual clinical practice with no criteria for therapy selection and no schedule of visits imposed.

To estimate outpatient cost of care, we linked patients with NHL identified in the iKnowMed EMR to US Oncology’s Claims Data Warehouse (CDW). The CDW repository houses all claims for services provided within the US Oncology network. Data include HCPCS/CPT (Healthcare Common Procedure Coding System/Current Procedural Terminology) codes and descriptions, date of service, quantity, amount billed, and primary payer. Data were de-identified and accessed in compliance with the Health Insurance Portability and Accountability Act. Therefore, approval by an institutional review board was not required.

Study population
Using a retrospective cohort design, we identified a pool of 2005 patients with f-NHL in iKnowMed who achieved partial or complete remission or had documented stable disease or progression from 1 July 2006 to 30 December 2009. Treatment response and PD were classified according to standard response criteria [25]. Patients were categorized into two cohorts depending on their experience of PD during the study catchment period. Incidence of PD was identified by a documented disease status of ‘progressive disease’ following a period of remission or stable disease. Patients who did not progress were identified by a documented disease status of ‘partial remission’, ‘complete remission’, or ‘stable disease’.

There were 282 (14%) patients with PD and 1723 (86%) without. Of these, we linked 1865 (93%) to the CDW. We excluded 36 patients (five with PD and 31 without PD) who were enrolled in another clinical trial or received treatment for another cancer, and 848 patients (nine with PD and 839 without PD) who were identified as having second opinion/consult only. The identification of second opinion/consult only cases was based on having fewer than 30 days of total follow-up in iKnowMed with incomplete demographic and clinical characteristics. After applying the inclusion and exclusion criteria, a total of 1002 patients with f-NHL were included in the final study population: 734 in the ‘no PD’ cohort and 268 patients in the ‘PD’ cohort.

Follow-up time was censored at the last entry for disease status, end of 12 months, or study end (31 December 2010). To calculate the cost of progression, we adopted a phase of care approach using a 6-month window from the date of disease progression, as the majority of re-treatment costs are usually seen within this time period [26–28]. The study index date (baseline) was the date of PD or the initial date in the study catchment period for those with no PD. Data were collected at baseline on patient demographics (age at diagnosis and gender), clinical characteristics (stage at diagnosis, presence of B-symptoms, hemoglobin [HGB] levels, lactate dehydrogenase [LDH] levels, performance status, and nodal status) as well as payer type. The number of lymph nodes and extent of spread to the lymph nodes is captured in the iKnowMed data based on the TNM staging, which captures the extent of the tumor (T), extent of spread to the lymph nodes (N), and presence of distant metastasis (M). For laboratory values, performance status, and nodal status, we captured the closest entry within 14 days of the index date.

Statistical analysis
Patients were described at baseline with respect to demographic and clinical characteristics overall and stratified by progression status. \( \chi^2 \) tests for categorical variables and \( t \)-tests for continuous variables determined statistically significant differences by progression status.

Costs were estimated based on unadjusted 2007 Medicare reimbursement rates, Geographic Practice Cost Index (GPCI) 93. While reimbursement rates were available for the large majority (97%) of charges, for the remaining charges missing a Medicare rate we imputed costs using a median charge-to-cost ratio that was calculated using all codes for which Medicare reimbursement was available. Costs were calculated using a standard cost per patient per month (PPPM) metric. For months in which a patient did not accrue costs, a value of zero was applied to ensure that those patient-months were included in the denominator for the costs PPPM calculations. Costs were reported overall and by health resource category. Unadjusted costs were compared between PD cohorts using the Mann–Whitney \( U \)-test.

We developed econometric models to adjust for clinical and demographic differences that may confound the observed association between progression status and cost of care. A backward elimination approach was utilized to identify significant predictors of total costs. Age at diagnosis, gender, stage at diagnosis, presence of B-symptoms, baseline HGB, baseline LDH, number of positive lymph nodes, and baseline performance status were considered as possible covariates. PD was included as an indicator variable. Standard model diagnostics was carried out including tests for multicollinearity and heteroscedasticity, and appropriate estimation methods were employed (e.g. calculating heteroscedasticity-robust standard error [SE]) [29].
To provide a more comprehensive evaluation of the extent of HRU for patients who did and did not progress, we compared the frequency at which patients received care over a 6-month period. Using claims data, we compared the number of billed outpatient physician visits, acute care visits (inpatient and emergency room [ER] admissions), outpatient chemotherapy infusion visits, and outpatient laboratory procedures by progression status. These frequencies were measured on a PPPM basis and t-tests/Mann–Whitney U-tests (depending on the normality of data) were used to determine statistical significance. Statistical analyses were conducted with SPSS version 15 and SAS version 9.1. All statistical tests were interpreted at \( \alpha = 0.05 \), two-tailed.

**Results**

Table I shows the baseline clinical and demographic characteristics of patients overall and by progression status.

| Characteristic                     | Total (n = 1002) | No progression (n = 734) | Progression (n = 268) | p-Value |
|------------------------------------|-----------------|-------------------------|------------------------|---------|
| Age at diagnosis, n (%)            |                 |                         |                        |         |
| < 55                               | 333 (33)        | 258 (35)                | 75 (28)                | 0.10    |
| 55-65                              | 313 (31)        | 222 (30)                | 91 (34)                |         |
| > 65                               | 356 (36)        | 254 (35)                | 102 (38)               |         |
| Mean age                           | 60.1            | 59.6                    | 61.3                   |         |
| Median age (range)                 | 61 (21-91)      | 60 (21-91)              | 61 (27-90)             | 0.10    |
| Gender, n (%)                      |                 |                         |                        |         |
| Female                             | 565 (56)        | 430 (59)                | 135 (50)               | 0.02    |
| Male                               | 437 (44)        | 304 (41)                | 133 (50)               |         |
| Stage, n (%)                       |                 |                         |                        |         |
| I                                  | 187 (20)        | 147 (21)                | 40 (16)                | 0.06    |
| II                                 | 198 (21)        | 150 (22)                | 48 (19)                |         |
| III                                | 234 (25)        | 170 (25)                | 64 (25)                |         |
| IV                                 | 327 (35)        | 223 (32)                | 104 (41)               |         |
| Missing                            | 56              | 44                      | 12                     |         |
| B-symptoms, n (%)                  |                 |                         |                        |         |
| No                                 | 812 (85)        | 601 (87)                | 211 (82)               | 0.11    |
| Yes                                | 138 (15)        | 93 (13)                 | 45 (18)                |         |
| Missing                            | 52              | 40                      | 12                     |         |
| HGB < 12*, n (%)                   |                 |                         |                        |         |
| No                                 | 668 (81)        | 502 (85)                | 166 (73)               | < 0.0001|
| Yes                                | 152 (19)        | 90 (15)                 | 62 (27)                |         |
| Missing                            | 182             | 142                     | 40                     |         |
| Elevated LDH*, n (%)               |                 |                         |                        |         |
| No                                 | 477 (86)        | 353 (89)                | 124 (80)               | 0.01    |
| Yes                                | 76 (14)         | 45 (11)                 | 31 (20)                |         |
| Missing                            | 449             | 336                     | 113                    |         |
| 4 + positive nodes, n (%)          |                 |                         |                        |         |
| No                                 | 543 (67)        | 412 (70)                | 131 (58)               | 0.0008  |
| Yes                                | 272 (33)        | 176 (30)                | 96 (42)                |         |
| Missing                            | 187             | 146                     | 41                     |         |
| ECOG PS*, n (%)                    |                 |                         |                        |         |
| 0                                  | 581 (68)        | 445 (71)                | 136 (60)               | 0.0005  |
| 1                                  | 209 (25)        | 145 (23)                | 64 (28)                |         |
| 2 +                                | 60 (7)          | 33 (5)                  | 27 (12)                |         |
| Missing                            | 152             | 111                     | 41                     |         |
| Payer type                         |                 |                         |                        |         |
| Private                            | 438 (44)        | 330 (45)                | 108 (40)               | 0.06*   |
| Medicare                           | 537 (53)        | 381 (52)                | 156 (58)               |         |
| Medicaid                           | 9 (1)           | 6 (1)                   | 3 (1)                  |         |
| Other                              | 18 (2)          | 17 (2)                  | 1 (0)                  |         |
| Follow-up time, n (%)              |                 |                         |                        |         |
| < 12 months                        | 56 (6)          | 28 (4)                  | 30 (11)                |         |
| ≥ 12 months                        | 938 (94)        | 700 (98)                | 238 (89)               |         |
| Mean follow-up time, months        | 35.1            | 37.0                    | 29.8                   |         |
| Median follow-up, months (range)   | 37 (1-53)       | 39 (3-53)               | 32 (1-53)              |         |
| Alive at end of follow-up, n (%)   | 983 (99)        | 725 (99.6)              | 258 (97)               |         |

HGB, hemoglobin; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group Performance Status.

*Based on entry in iKnowMed closest to index date (± 14 days).
and seven (4%) received chemotherapy only. Among the non-PD group, 195 (27%) received infusion therapy. The majority of these patients \( (n = 147; 75\%) \) received rituximab monotherapy, while 44 (23%) received rituximab in combination with chemotherapy and four (2%) received chemotherapy alone. To further verify why some non-PD patients received chemotherapy other than maintenance rituximab, we conducted an electronic chart review of a random sample of this group and found that chemotherapy administered was typically given to complete a planned chemotherapy regimen following treatment response (i.e. consolidation). For example, the typical non-PD patient who had chemotherapy and rituximab charges actually only received chemotherapy for a short time following treatment response and then subsequently received rituximab maintenance therapy.

Figure 1 shows the cumulative total cost over 12 months by progression status. The cumulative 6-month total cost for patients with PD was $21,621 vs. $5226 for non-PD patients. At 12-months, the cumulative total cost for patients with PD was $30,890 vs. $8704 for non-PD patients. Table III presents a comparison of mean costs PPPM by progression status. Average costs PPPM over the 6-month follow-up period for patients with PD were $2667 more than for non-PD patients \( (p < 0.001) \), with a relative cost four times higher. Differences in cost were significant in all categories.

In a level-level multivariable regression model (Table IV) adjusting for baseline hemoglobin level, number of positive lymph nodes at diagnosis, baseline performance status, and progression status remained significantly associated with total outpatient costs. PD was associated with an increased cost of $2557 per month, all else being equal. Due to the presence of heteroscedasticity as diagnosed using the Breusch-Pagan test, this model includes robust-SEs. In another model including log-transformed cost as the dependent variable

### Table II. Description of infusion therapy by progression status after index date.

| Infusion therapy | Total \( (n = 1002) \) | No progression \( (n = 734) \) | Progression \( (n = 268) \) |
|------------------|------------------------|-----------------------------|-----------------------------|
| Infusion therapy |                        |                             |                             |
| No               | 621 (61.9%)            | 539 (73.4%)                 | 82 (30.5%)                  |
| Yes              | 381 (38.1%)            | 195 (26.5%)                 | 186 (69.4%)                 |
| Rituximab monotherapy | 216 (21.6%) | 147 (55.4%)                 | 69 (31.5%)                  |
| Rituximab-chemotherapy | 154 (15.4%) | 44 (22.5%)                  | 110 (59.1%)                 |
| Chemotherapy only | 4 (2.1%)               | 2 (1.5%)                    | 2 (3.8%)                    |

### Chemotherapy agents

- **Rituximab-chemotherapy**: 154
- **Cyclophosphamide**: 108
- **Vincristine**: 101
- **Doxorubicin**: 41
- **Fludarabine**: 23
- **Other**: 203

- **Chemotherapy only**: 4
- **Cyclophosphamide**: 6
- **Vincristine**: 4
- **Doxorubicin**: 2
- **Etoposide**: 1
- **Other**: 10

| Chemotherapy agents | Total \( (n = 1002) \) | No progression \( (n = 734) \) | Progression \( (n = 268) \) |
|---------------------|------------------------|-----------------------------|-----------------------------|
| Rituximab-chemotherapy | 154 | 44 | 110 |
| Cyclophosphamide | 108 | 33 | 75 |
| Vincristine | 101 | 32 | 69 |
| Doxorubicin | 41 | 16 | 25 |
| Fludarabine | 23 | 3 | 20 |
| Other | 203 | 46 | 157 |
| Chemotherapy only | 4 | 2 | 4 |
| Cyclophosphamide | 6 | 2 | 4 |
| Vincristine | 4 | 1 | 3 |
| Doxorubicin | 2 | 1 | 1 |
| Etoposide | 1 | 1 | 0 |
| Other | 10 | 2 | 8 |

![Figure 1. Cumulative 12-month total cost by progression status.](image1.png)
Table III. Six-month mean cost per patient per month overall and by category.

| Service                  | No progression (n = 734) | Progression (n = 268) | \(C_P - C_{NP}\) | \(C_P/C_{NP}\) | p-Valuea |
|--------------------------|--------------------------|-----------------------|------------------|----------------|----------|
| Overall cost             | 859.96                   | 3527.4                | 2667.4           | 4.10           | <0.001   |
| Outpatient visits        | 36.68                    | 99.92                 | 63.24            | 2.72           | <0.001   |
| Acute care†              | 2.46                     | 24.14                 | 21.68            | 9.81           | <0.001   |
| Chemotherapy             | 655.75                   | 2495.01               | 1839.26          | 3.8            | <0.001   |
| R-mono                   | 487.07                   | 849.50                | 362.43           | 1.74           | <0.001   |
| R-chemo                  | 166.07                   | 1610.86               | 1444.79          | 9.69           | <0.001   |
| Chemo                    | 2.61                     | 34.65                 | 32.04            | 13.27          | <0.001   |
| Other medication         | 101.86                   | 700.28                | 598.42           | 6.87           | <0.001   |
| Laboratories             | 11.35                    | 28.53                 | 17.18            | 2.51           | <0.001   |
| Minor procedures         | 2.79                     | 8.79                  | 6.00             | 3.15           | <0.001   |
| Other                    | 0.59                     | 3.02                  | 2.43             | 5.11           | <0.001   |
| XRT                      | 15.07                    | 71.27                 | 38.93            | 4.72           | <0.001   |
| RAD non-XRT              | 32.59                    | 95.41                 | 62.82            | 2.92           | <0.001   |

\(C_P\), cost of progression; \(C_{NP}\), cost of not progressing; R-mono, rituximab monotherapy; R-chemo, rituximab-chemotherapy; Chemo, chemotherapy only; XRT, external radiation treatment; RAD non-XRT, radiation other than XRT.

* Mann–Whitney U-test.
† Inpatient and ER visits.

(Table IV), PD was found to be independently associated with a two-fold higher cost after adjusting for potential confounders.

Table V presents health resource utilization by progression status. Patients who experienced PD had a 23% higher frequency of outpatient physician visits than non-PD patients \((p < 0.001)\). A two-fold higher frequency was observed for outpatient laboratory visits \((p < 0.001)\) in PD vs. non-PD patients. Patients with PD were significantly more likely to receive chemotherapy than non-PD patients \((72\% \text{ vs. } 29\%, p < 0.001)\). Further, among patients who received chemotherapy, those who progressed had a significantly higher frequency of chemotherapy infusion visits \((p < 0.001)\), suggesting that patients who progress receive more intensive chemotherapy regimens than those who do not progress \(\text{the majority of whom receive maintenance rituximab}\). Similarly, patients with PD were significantly more likely to have an inpatient admission or ER visit than non-PD patients \(\text{18\% vs. } 4\%, p < 0.001)\), although the mean number of acute care visits PPPM did not differ by progression status.

**Discussion**

For a relatively indolent cancer such as f-NHL, for which treatment options range from watchful waiting to costly stem-cell transplant, rational treatment selection should include consideration of both the medical efficacy and the economic outcomes of the available treatment options. Results of this retrospective study highlight and quantify the economic costs of progression among patients with f-NHL treated within an outpatient community-based setting. Using linked EMR and claims data from a large cohort of patients, we provide further evidence to support the hypothesis that treatment strategies that delay or prevent progression not only improve clinical outcomes but also provide substantial economic benefits in lowering the costs of care in NHL.

Findings from this study add to the literature in that it is the first study to estimate the cost of progressed f-NHL and the burden of progression on the healthcare system. The few studies that have assessed the economic burden of NHL are subject to the following limitations: restricted to specific geographic regions, clinical trial setting, or a single employer; did not differentiate between NHL subtypes; and did not differentiate between treatment phase or progression status \([30–32]\). A recent study by Kutikova and colleagues evaluated medical costs by NHL subtype \((\text{indolent and aggressive})\), but examined costs of progression only for patients with aggressive NHL \([24]\). The current analysis accounts for these limitations and provides data for the cost of progression in a diverse group of patients with indolent NHL.

The present study showed that patients with f-NHL who progressed were more likely to have been diagnosed with advanced disease, have four or more positive lymph nodes,
poor performance status, and high LDH and low HGB levels, consistent with other studies [33–35].

The overall crude cumulative total cost of progression over a 12-month follow-up period was $30 890, compared to $8704 for non-PD patients. The mean cost PPPM among those who progressed was $2667 more than for patients who did not progress (p < 0.001), with a relative cost nearly four times higher. In multivariate analysis, PD remained significantly associated with a two-fold higher cost, adjusting for differences in clinical factors. There are few studies of NHL costs with which to compare the results of this present study. Further, different patient populations, costing methodologies, and specific objectives make direct comparisons across studies difficult. In the only published US study of direct per-patient costs for f-NHL, Gleeson et al. estimated that the total direct costs for f-NHL in the first year following diagnosis was $36 000 [36]. In another study, the mean cost of treatment failure in aggressive NHL was $14 174 PPPM [24], which is significantly higher than the cost of progression estimated among patients with f-NHL in this study. However, different subsets of the patient population with NHL (aggressive vs. indolent) were considered, and while our study focused solely on outpatient costs, the study by Kutikova et al. considered inpatient costs as well [24].

We found that patients who progressed had significantly higher frequencies of outpatient physician visits, laboratory procedures, acute care visits, and intensive chemotherapy regimens compared to non-PD patients. This finding is supported by results from Kutikova et al. who showed that patients with both aggressive and indolent NHL had significantly higher resource use than controls [24].

In interpreting the findings, several factors need to be considered. First, although data were collected from geographically dispersed community oncology practices, it is subject to selection bias due to convenience sampling where the study population may differ in unknown ways from the underlying patient population. Second, potential confounding variables such as race, ethnicity, and income were not available, which limited the number of covariates that could be included in the multivariate analysis. We followed patients for a maximum of 6 months, which may have led to an underestimation of reported costs and the rate of treatment failure or PD. While the claims data used to estimate costs for this analysis included primarily outpatient medical oncology services, we also captured charges for radiologic services and inpatient consultation visits. However, costs for these services may be underestimated due to the possibility that patients may have received these outside of the US Oncology network.

However, despite these limitations, this study provides new information regarding the economic impact of PD in patients with f-NHL. As survival improves, the number of patients living with the disease is expected to rise. Patients whose disease has progressed may still have a relatively long survival with conventional management [33]. As a result, physicians will continue to navigate an increasing array of treatment options for this clinically heterogeneous group of patients. A better understanding of the economic outcomes associated with the disease and its treatment is essential in minimizing the burden to patients, caregivers, and society. Furthermore, while there is increasing scrutiny of the direct costs of prolonged treatment with targeted therapy, it is important to weigh these costs relative to the potential economic benefit of delaying progression. In this study, we objectively quantified the cost of PD, which plausibly could be offset by therapies that, while costly, have been demonstrated to yield significant clinical benefit in terms of delayed progression.

**Acknowledgements**

The authors would like to thank Steven Grushkus, PhD, for input on the initial study design and analysis plan and Jia Li, PhD, for thoughtful review and comments on the manuscript. This research was sponsored by Genentech, Inc., South San Francisco, California.
Potential conflict of interest: Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/1al.

References
[1] The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997;90:3909–3918.
[2] Altekruse S, Kosary C, Krapcho M, et al. SEER cancer statistics review, 1975–2007. Bethesda, MD: National Cancer Institute; 2010.
[3] Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993;20:75–88.
[4] Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019–5026.
[5] Italiano A, Thyss A. Follicular lymphoma: a therapeutic update. Bull Cancer 2005;92:ES7–ES4.
[6] Johnson JW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140–147.
[7] Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma. Drugs 2007;67:333–350.
[8] Vose JM. Personalized immunotherapy for the treatment of non-Hodgkin’s lymphoma: a promising approach. Hematol Oncol 2006;24:47–55.
[9] Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064–3071.
[10] Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
[11] Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
[12] Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579–4586.
[13] Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
[14] Maloney DG. What is the role of maintenance rituximab in follicular NHL? Oncology (Williston Park) 2008;22:20–26; discussion 26, 29, 33–24.
[15] Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009;27:1607–1614.
[16] Ghielemini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416–4423.
[17] Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 2002;29:25–29.
[18] van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
[19] van Oers MH, Van Gielbeke M, Giurgena L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20861 phase III randomized intergroup study. J Clin Oncol 2010;28:2853–2858.
[20] Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol 2010;28(15 Suppl.): Abstract 6004.
[21] Salles GA, Catalano JF, Feugier P, et al. Rituximab maintenance for 2 years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study. Haematologica 2010;95(Suppl. 2): Abstract 0557.
[22] Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008;49:227–236.
[23] Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65–70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma 2008;8:166–170.
[24] Kutikova L, Bowman L, Chang S, Long SR, Arning M, Crown WH. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leuk Lymphoma 2006;47:1535–1544.
[25] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
[26] Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999;37:1249–1259.
[27] Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828–841.
[28] Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630–641.
[29] Hayes AF, Cai L. Using heteroskedasticity-consistent standard error estimators in OLS regression: an introduction and software implementation. Behav Res Methods 2007;39:709–722.
[30] Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M. The costs of cancer to a major employer in the United States: a case-control analysis. Am J Manag Care 2000;6:1243–1251.
[31] Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40(IV):104–117.
[32] Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997;18:51–76.
[33] Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470–1480.
[34] Perea G, Altes A, Montoto S, et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005;16:1508–1513.
[35] Montoto S, Lopez-Guillermo A, Ferrer A, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol 2002;13:523–530.
[36] Gleeson M, Carolina R, Danese M, Knopf KB. Cost of follicular lymphoma (FL) in Medicare patients. J Clin Oncol 2008;26(Suppl.): Abstract 6834.